RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Generic substitution of epinephrine auto-injectors
Patient and caregiver perceptions and attitudes
Ray, S. E., Boudewyns, V., Oguntimein, O., Conti, D. S., Malik, R. A., Srivastava, I., & Feibus, K. B. (2024). Generic substitution of epinephrine auto-injectors: Patient and caregiver perceptions and attitudes. Journal of Allergy and Clinical Immunology: Global, (1). https://doi.org/10.1016/j.jacig.2023.100170
Background: It is important to understand and address patient and caregiver perceptions about and attitudes toward generic substitution of drug-device combination products. Objective: The goal of this study was to explore how differences in design and usability features of epinephrine auto-injectors (EAIs) affect patients’ and caregivers’ views of product quality, efficacy, and device usability in an emergency setting and to better understand attitudes about and perceptions of EAI substitution. Methods: This qualitative, enhanced focus group study was conducted in the United States among adult and adolescent EAI users. A journey mapping exercise was used to explore patient and caregiver perceptions of and barriers to switching to a generic EAI. Discussion topics also focused on questions participants would ask, challenges they would face, and actions they would take if they were switched to a generic EAI. Results: While patients and caregivers were interested in the potential cost savings and increased access to treatment offered by generic EAIs, they wanted to be informed by their prescriber or pharmacist about generic substitution before or when it occurs. In terms of design differences, participant feedback most often related to differences in look and feel (e.g., size, force to execute user tasks, hand grip) or functionality and design differences (e.g., generic has a twist-off cap at the needle end, and EpiPen does not). Conclusion: Outcomes from these focus groups suggest opportunities for the Food and Drug Administration, healthcare professional organizations, and patient advocacy organizations to improve generic drug literacy among adults, adolescents, and healthcare providers.